NASDAQ:GOSS Gossamer Bio Q1 2024 Earnings Report $1.15 -0.03 (-2.54%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.15 +0.00 (+0.35%) As of 05/21/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Gossamer Bio EPS ResultsActual EPS-$0.19Consensus EPS -$0.19Beat/MissMet ExpectationsOne Year Ago EPSN/AGossamer Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGossamer Bio Announcement DetailsQuarterQ1 2024Date5/7/2024TimeN/AConference Call DateTuesday, May 7, 2024Conference Call Time10:01AM ETConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Gossamer Bio Earnings HeadlinesGossamer Bio (NASDAQ:GOSS) Stock Price Expected to Rise, The Goldman Sachs Group Analyst SaysMay 18, 2025 | americanbankingnews.comEarnings call transcript: Gossamer Bio exceeds Q1 2025 revenue forecastsMay 17, 2025 | uk.investing.comHere’s your answerPorter Stansberry is stepping into the spotlight — and putting real skin in the game. For the first time ever, he’s opening the doors to a live, real-money trading account, managed transparently with the same strategies he’s used to build long-term wealth. Every 90 days, he and his lead analyst release a new tranche of trades designed for serious investors who don’t want to babysit the market. The goal: income, downside protection, and asymmetric upside.May 22, 2025 | Porter & Company (Ad)Cantor Fitzgerald maintains Overweight on Gossamer Bio stockMay 17, 2025 | uk.investing.comGOSSAMER BIO Earnings Results: $GOSS Reports Quarterly EarningsMay 17, 2025 | nasdaq.comGossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comSee More Gossamer Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gossamer Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gossamer Bio and other key companies, straight to your email. Email Address About Gossamer BioGossamer Bio (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.View Gossamer Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds Upcoming Earnings Autodesk (5/22/2025)Analog Devices (5/22/2025)Copart (5/22/2025)Intuit (5/22/2025)Ross Stores (5/22/2025)Workday (5/22/2025)Toronto-Dominion Bank (5/22/2025)AutoZone (5/27/2025)Bank of Nova Scotia (5/27/2025)NVIDIA (5/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
